Blog

Nelson Advisors interviewed by Healthcare Business International for their 'What does the £900M NHS AI framework mean for UK healthcare?' storyNelson Advisors partner Lloyd Price was interviewed by Healthcare Business International for their 'What does the £900M NHS AI framework mean for UK healthcare?' story.Source: <a href="https://www.healthcarebusinessinternational.com/what-does-the-900m-nhs-ai-framework-mean-for-uk-healthcare/">https://www.healthcarebusinessinternational.com/what-does-the-900m-nhs-ai-framework-mean-for-uk-healthcare/</a>What it means for investorsFor investors and suppliers, the framework is widely seen as a significant market signal, raising both the bar for entry and the visibility of NHS demand for AI.“The framework centralises procurement, raising the bar for regulatory approvals and data requirements,” Lloyd Price, partner at M&amp;A advisory firm Nelson Advisors, a Boutique Investment Bank focused exclusively on the healthtech and medtech sectors, told HBI.&nbsp;“For investors, this creates clearer visibility on emerging winners, those that secure framework access and start winning bids are likely to accelerate growth rapidly and compound advantage,” he added.Price also highlighted that the framework could improve supplier economics over time byreducing reliance on long and costly enterprise sales cycles. “For private equity, that’svery attractive,” he said.Meanwhile, Price noted that existing supplier contracts in hospitals could slow near term disruption.“Even if you get onto the framework, hospitals may already have long-term contracts in place with incumbents like Siemens or Philips. So access is not immediate.”Market structure and long-term outlook&nbsp;Despite these challenges, the framework marks a structural shift in the NHS AI market.Price added that the most immediate demand will likely be concentrated in imaging, diagnostics, administrative automation and workforce optimisation.Nelson Advisors &gt; European MedTech and HealthTech Investment BankingNelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. <a href="http://www.nelsonadvisors.co.uk">www.nelsonadvisors.co.uk</a>Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis &amp; predictions @ <a href="https://www.healthcare.digital">https://www.healthcare.digital&nbsp;</a>Nelson Advisors publish Europe’s leading HealthTech and MedTech M&amp;A Newsletter every week, subscribe today! <a href="https://lnkd.in/e5hTp_xb">https://lnkd.in/e5hTp_xb</a>&nbsp;Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. <a href="http://www.nelsonadvisors.co.uk">www.nelsonadvisors.co.uk</a>#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTechNelson Advisors LLPHale House, 76-78 Portland Place, Marylebone, London, W1B 1NT<a href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a><a href="mailto:paul@nelsonadvisors.co.uk">paul@nelsonadvisors.co.uk</a>Meet Nelson Advisors @ 2026 EventsDigital Health Rewired &gt; March 2026 &gt; Birmingham, UK&nbsp;NHS ConfedExpo &nbsp;&gt; June 2026 &gt; Manchester, UK&nbsp;HLTH Europe &gt; June 2026, Amsterdam, NetherlandsHIMSS AI in Healthcare &gt; July 2026, New York, USABits &amp; Pretzels &gt; September 2026, Munich, Germany &nbsp;World Health Summit 2026 &gt; October 2026, Berlin, GermanyHealthInvestor Healthcare Summit &gt; October 2026, London, UK&nbsp;HLTH USA 2026 &gt; October 2026, USABarclays Health Elevate &gt; October 2026, London, UK&nbsp;Web Summit 2026 &gt; November 2026, Lisbon, Portugal &nbsp;MEDICA 2026 &gt; November 2026, Düsseldorf, GermanyVenture Capital World Summit &gt; December 2026 Toronto, Canada

What does the £900M NHS AI framework mean for UK healthcare? Nelson Advisors interviewed by Healthcare Business International

The speculation is now official, by a London investment banking firm, confirming this Editor’s view: Oracle, to become an “AI Infrastructure Landlord” in their apt term, has to sell off what was Cerner and the EHR operation. &nbsp;The London investment banking firm Nelson Advisors has taken a deep yet remarkably easy to digest analysis on a potential sale. Highlights are below. The paper is one long web page, not a deck of 50 pages. It is well worth your reading time. Source: <a href="https://telecareaware.com/selling-oracle-healths-ehr-what-are-the-potential-buyers-their-odds-and-price/">https://telecareaware.com/selling-oracle-healths-ehr-what-are-the-potential-buyers-their-odds-and-price/</a> The speculation is now official, by a London investment banking firm, confirming this Editor’s view: Oracle, to become an “AI Infrastructure Landlord” in their apt term, has to sell off what was Cerner and the EHR operation.&nbsp;That train is now approaching, though realistically, no one knows when it is due.Oracle must reduce the extent of its “liquidity and capital expenditure crisis” in order to stay in the AI Game. Layoffs of 30,000 staff, or 18% of their global employees, is not enough. A fresh financing of $16 billion from the PIMCO bond fund and others cannot relieve the financial stress created by a previous estimated $72 to $100 billion in previous debt load and payments, so significant that banks refused to lend to still-profitably Oracle. And the AI transformation itself is high risk. Oracle owes OpenAI alone $553 billion in remaining performance obligations, and it has obligations to Meta as well. Add to this the long taffy pull–the years-long process of building, chip expenditure, then making a data center operational and generating cash. Add them together, and they are polite words for “rock and a hard place” or a Very Dark Corner.The London investment banking firm Nelson Advisors has taken a deep yet remarkably easy to digest analysis on a potential sale. Highlights are below. The paper is one long web page, not a deck of 50 pages. It is well worth your reading time.Background: Cerner was bought four years ago in the go-go days of June 2022 for $28 billion. Cerner had an aging EHR and a deteriorating market share. Recently it’s plummeted to a 27% market share versus Epic’s 48% in large health systems. Oracle’s interest was not only in health, but also the health data Cerner contained. The plans were to update the software based EHR to a cloud-native data platform as the linchpin of Healthcare Transformation (Ed. note), except that integration proved to be slow and far more expensive than estimated.Oracle also inherited from Cerner two huge and impossible to escape Federal obligations: the Military Health System EHR and the Veterans Health Administration EHR Modernization, two separate but mandatorily interoperable systems. MHS was the first implemented and is now &nbsp;completed, but remains an obligation. The VA EHRM, as TTA has chronicled, started rolling out in 2020 and by 2023 was halted after five implementations Due to Disaster. It resumed in April 2026. The VA and Congressional process for funding now has tight guardrails in place on continuance. &nbsp;Who will buy the Oracle/Cerner EHR operation is the question. For how much isn’t as clear. Selling Oracle Cerner “represents the most significant “lump sum” of liquidity available. In the Nelson analogy, Oracle took the Cerner cow, milked it of data to feed its data into its LLMs, and no longer wants knackered ol’ Bessie even rejuvenated by the cloud. (In this Editor’s view, Oracle knows it is fighting a losing battle against Epic, which does privately pretty much what it wants and plans to stay that way.)The obvious group of potential buyers are ‘hyperscalers’ who view health data as the Next Frontier. They already have feet in this healthcare pond. They also meet approved FedRAMP High security requirements for the VA and MHS contracts. Equally, they all have drawbacks.Microsoft seems the most logical. It already has a huge footprint and expertise within health systems courtesy of ambient scribe Nuance/DAX Copilot and cloud computing platform Azure.Conflict #1: Epic uses Azure Conflict #2: FTC would likely challenge the acquisition based on this huge footprint. Amazon is also engaged in healthcare, but not with health systems. It has Amazon Health Services comprising Pharmacy, One Medical, and DTC telehealth services. (Editor’s note: not mentioned here is that Amazon Health has a new leader, Dr. Roy Schoenberg, with experience in Federal contracts via Amwell for the Defense Health Agency and MHS.)Conflict: Amazon Web Services is an established vendor in other areas of health systems, and acquiring an EHR could be seen as too much under one roof. Problem: no experience with EHRs (same as Oracle) nor highly regulated health systems. The scale of the MHS/VA implementation and academic hospitals would be a steep learning curve with little existing precedent or credibility. Google certainly has the size and resources, and could position the EHR to rival both Microsoft and Epic.&nbsp;Conflict #1: Cultural. Google moves fast and healthcare slowly. Conflict #2: Lacks the enterprise sales and support needed to service health systems. It doesn’t have a service culture. Editor’s note: Google has tried and failed to be a healthcare giant at least twice. It doesn’t seem to fit. Nelson also looked at two outliers, UnitedHealth Group/Optum and the hospital groups HCA or CommonSpirit Health. Both would be vertical integrators. Hospital groups do not have the margin nor borrowing power to make the move. UHG and their Optum operation face cash crunches and ongoing Federal scrutiny. (Had this been a few years ago under a different management, this would have been on strategy.)Another outlier from the international space is SAP. Their aim would be global expansion into the Middle East and Europe with another asset their enterprise resource planning (ERP) expertise. Their problem? Lack of experience in the highly regulated US environment. In the Nelson view, the US Government could be the make/break for any deal.The final destination? Private equity. Nelson looked at five PE players in the healthcare space: Thoma Bravo, Francisco Partners, Bain Capital, Blackstone, and New Mountain Capital. Even with their considerable individual assets, it would likely take a consortium to buy Oracle Health in a $20 to $25 billion deal. Nelson rates this as the most likely scenario as long as a consortium could be formed and it can be seen as a turnaround. The drawbacks are a governance structure and the real lack of an exit strategy. The lower price could be made palatable to Oracle if they retained the Oracle Cloud Infrastructure (OCI) network and the Oracle Autonomous Database revenue streams.Source: <a href="https://telecareaware.com/selling-oracle-healths-ehr-what-are-the-potential-buyers-their-odds-and-price/">https://telecareaware.com/selling-oracle-healths-ehr-what-are-the-potential-buyers-their-odds-and-price/</a>

Nelson Advisors featured in Telehealth & Telecare Aware article 'Selling Oracle Health’s EHR–what are the potential buyers, their odds, and price?'

Nelson Advisors referenced in leading French HealthTech publication Caducee.net's artcicle 'Doctolib-Medicus : le pari du logiciel clinique pour les généralistes du NHS'.Source: <a href="https://www.caducee.net/actualite-medicale/16903/doctolib-medicus-le-pari-du-logiciel-clinique-pour-les-generalistes-du-nhs.html" data-mce-href="https://www.caducee.net/actualite-medicale/16903/doctolib-medicus-le-pari-du-logiciel-clinique-pour-les-generalistes-du-nhs.html">https://www.caducee.net/actualite-medicale/16903/doctolib-medicus-le-pari-du-logiciel-clinique-pour-les-generalistes-du-nhs.html</a>Pourquoi le Royaume-Uni, pourquoi maintenant L’entrée britannique de Doctolib s’inscrit aussi dans une trajectoire financière et européenne. Pour Nelson Advisors, cabinet spécialisé dans les fusions-acquisitions, les partenariats et les investissements en santé numérique, le rachat de Medicus constituerait une pièce critique du dispositif de Doctolib dans la perspective d’une introduction en Bourse, ou initial public offering (IPO), anticipée.[16] Cette lecture doit rester à sa juste place : il s’agit d’une analyse de marché, non d’une annonce confirmée par le groupe.Elle éclaire néanmoins le calendrier. Nelson Advisors replace l’opération dans un moment de consolidation européenne, avec d’un côté la pression réglementaire sur les marchés historiques de Doctolib, notamment en Allemagne, et de l’autre le précédent italien de Dottori.it, présenté comme un modèle d’expansion transfrontalière.[16] Sous cet angle, Medicus devient un actif de crédibilité : il doit montrer que Doctolib peut passer de l’intermédiation patient-médecin à une infrastructure clinique européenne, dans un marché où les investisseurs valorisent les revenus logiciels récurrents et l’ancrage dans les systèmes publics.14. Caducee.net, MedGPT : un baromètre qui éclaire les tensions du premier recours, 17 mars 2026.15. Pulse Today, NHS England approves new clinical IT system for general practice, 26 juin 2025.16. Nelson Advisors, Doctolib’s acquisition of Medicus Health to enter the UK market, 6 mai 2026.17. SPPG, Department of Health, Northern Ireland, NI GP clinical system change, page consultée le 31 mai 2026.18. iatroX, Dr Kola Tytler, Doctolib, Medicus and the Race to Own the Digital Consultation, 6 mai 2026.

Nelson Advisors referenced in leading French HealthTech publication Caducee.net's artcicle 'Doctolib-Medicus : le pari du logiciel clinique pour les généralistes du NHS'

Nelson Advisors featured in The Institute of Chartered Accountants in England and Wale 'Medical technology in the UK: industry profile'.Source: <a href="https://www.icaew.com/library/industry-profiles/medical-technology">https://www.icaew.com/library/industry-profiles/medical-technology</a>A profile of the UK medical technology industry, from ICAEW's Library &amp; Information Service. Contains information on recent performance, market segmentation, trends, challenges, opportunities, and more. Key takeaways The UK has a large and diverse medical technology industry, generating £48bn in turnover in 2023/24 and representing the largest life sciences subsector by company count and employment. The sector benefits from a strong research base and advances in areas such as AI and robotics, with Government policy identifying medical technology as a high-growth 'frontier' industry. Post-Brexit regulatory divergence and slow approval processes, together with complex and fragmented NHS procurement systems, continue to hinder innovation and create barriers to market. Demand is set to grow, particularly for innovative medical technologies, as the NHS responds to an ageing population, rising chronic disease and a shift towards prevention, community settings and digitally enabled healthcare. Access to finance remains a major hurdle for SMEs seeking to commercialise and scale-up, whilst rising manufacturing and sustainability costs add further pressure across the sector.In July 2025, the MHRA announced proposals to introduce international reliance routes to address some of the barriers arising from regulatory divergence. Under these plans, certain devices approved by trusted regulators in Australia, Canada and the United States would be eligible for a streamlined route to the UK market, an initiative welcomed by the sector. However, with reliance routes not expected to be fully operational until 2027, a key decision for manufacturers in 2026 according to Nelson Advisors is whether to invest in the existing UKCA process or wait for the streamlined international route, risking a delay in market entry.<a href="https://www.healthcare.digital/single-post/what-will-be-the-biggest-challenges-for-healthtech-and-medtech-companies-selling-in-to-the-nhs-in-20">https://www.healthcare.digital/single-post/what-will-be-the-biggest-challenges-for-healthtech-and-medtech-companies-selling-in-to-the-nhs-in-20</a>Scaling digital innovations within the NHS is currently challenging however, with around 90% of AI tools remaining confined to pilot phases according to Nelson Advisers. Complex procurement and local governance processes, alongside fragmented and outdated IT infrastructure, create significant barriers. As BCG also point out, inconsistent data-sharing and limited data integration across organisations hinder its use for insight generation, with gaps in NHS workforce capacity and digital skills further constraining the deployment of new technologies.<a href="https://www.healthcare.digital/single-post/ai-in-the-nhs-transformative-promise-v-s-operational-reality">https://www.healthcare.digital/single-post/ai-in-the-nhs-transformative-promise-v-s-operational-reality</a>ICAEW overviewFounded in 1880, ICAEW has a long history of serving the public interest and we continue to work with governments, regulators and business leaders globally. And, as a world-leading improvement regulator, we supervise and monitor more than 11,500 firms, holding them, and all ICAEW members and students, to the highest standards of professional competency and conduct.ICAEW is a founding member of Chartered Accountants Worldwide (CAW), a global family that connects over 1.8m chartered accountants and students in more than 190 countries. Together, we support, develop and promote the role of chartered accountants as trusted business leaders, difference makers and advisers.Source: <a href="https://www.icaew.com/library/industry-profiles/medical-technology" data-mce-href="https://www.icaew.com/library/industry-profiles/medical-technology">https://www.icaew.com/library/industry-profiles/medical-technology</a>

Nelson Advisors featured in The Institute of Chartered Accountants in England and Wale 'Medical technology in the UK: industry profile'

The release of Anthropic’s Claude Opus 4.8 on May 28th, 2026, represents a significant development in the deployment of frontier artificial intelligence within highly regulated industries, with profound implications for healthcare technology, clinical operations and the life sciences. Built upon a foundation of accelerated model upgrades, Claude Opus 4.8 positions Anthropic at the forefront of the enterprise AI sector. This position is supported by a historic sixty-five billion dollar Series H funding round that pushed the organisation’s post-money valuation to nine hundred sixty-five billion dollars. Driven by an annualised run-rate revenue crossing forty-seven billion dollars, this financial capital is backed by major infrastructure alliances, including memory chip giants Micron, Samsung and SK Hynix, as well as a thirty-six billion dollar custom-chip leasing arrangement structured by Apollo and Blackstone. &nbsp;&nbsp; For healthcare technology executives, clinical informatics officers, and pharmaceutical researchers, Claude Opus 4.8 provides a highly capable, reliable and legally compliant computational engine. The model is designed to handle complex, long-horizon clinical tasks, multi-omics biological data analysis and intricate revenue cycle workflows that previously exceeded the capabilities of generative systems. Strategic Synthesis and Architectural Outlook The integration of Claude Opus 4.8, Claude for Healthcare, and upcoming Mythos-class security tools presents a clear path forward for healthcare technology. While the model's reasoning capabilities, compliance integrations, and developer efficiency tools are impressive, achieving their full potential requires structured, deliberate implementation. To balance innovation with safety, compliance, and clinical rigour, healthcare and life sciences organisations should adopt a phased deployment strategy: Phase 1: Compliance Auditing and Tooling Governance (Weeks 1-2): Map all active AI developer surfaces to ensure no patient data is sent through unaligned consumer channels like the Claude Console. Administrators must ensure that BAAs cover all active APIs and that data retention is set to Zero Data Retention (ZDR) for any systems handling clinical recordsPhase 2: Secure API Gateway Deployment (Weeks 3-4): Build a dedicated API gateway layer to automate audit logging, manage credential scoping, and encrypt records before they reach the model. This ensures compliance with HIPAA Technical Safeguards while protecting the application layer.Phase 3: Administrative and Revenue Cycle Integration (Weeks 5-8): Connect the secure API to specialized registries like CMS, ICD-10, and NPI. Implement automated prior authorisation routing and claim appeal workflows to quickly reduce administrative backlogs and improve revenue cycle efficiency.Phase 4: Clinical Decision Support and R&amp;D Scaling (Weeks 9-12): Deploy customized clinical-insights assistants inside point-of-care EHRs and connect scientific tools like Benchling, PubMed, and ClinicalTrials.gov to accelerate research. All clinical summaries must provide clear, interactive citations so physicians can easily verify the source data.Phase 5: Automated Defensive Security Hardening (Ongoing): Establish automated, model-assisted security scans to continuously monitor legacy hospital hardware and third-party software, patching potential network vulnerabilities before they can be exploited. By implementing this structured, compliance-first approach, healthcare organisations can safely adopt Claude Opus 4.8 to reduce clinician burnout, streamline operations, and accelerate medical discoveries.Source: <a href="https://www.healthcare.digital/single-post/anthropic-claude-opus-4-8-technical-architecture-capabilities-and-implications-for-healthcare-tech">https://www.healthcare.digital/single-post/anthropic-claude-opus-4-8-technical-architecture-capabilities-and-implications-for-healthcare-tech</a>

Strategic Analysis of Anthropic Claude Opus 4.8: Technical Architecture, Capabilities and Implications for Healthcare Technology

In late 2021, amid a broader pandemic-fuelled surge in remote healthcare and virtual care solutions, electronics retailer Best Buy sought to expand its healthcare footprint under its "Best Buy Health" banner. The cornerstone of this healthcare expansion was the acquisition of Current Health, an at-home care and remote patient monitoring platform, for approximately $400 Million.&nbsp; &nbsp;&nbsp; At the time, the transaction was positioned as a synergistic masterstroke: Best Buy would combine Current Health's FDA-cleared wearable sensors and clinical platform with the retail giant's massive logistics infrastructure and the in-home tech support of its Geek Squad division. However, by June 2025, the retail giant shifted its strategy, divesting Current Health back to its original co-founder, Christopher McGhee, for an undisclosed sum, laying off healthcare staff and significantly scaling back its clinical ambitions.&nbsp; &nbsp; This strategic retreat highlights the profound challenges of merging retail business models with the highly regulated, clinically complex and financially volatile American healthcare sector.Strategic Lessons and Takeaways &nbsp;&nbsp; The rise and fall of Best Buy’s clinical healthcare experiment offers critical strategic lessons for corporate strategy at the intersection of retail, technology, and clinical medicine. &nbsp; Healthcare is Not a Transactional Consumer Good &nbsp;&nbsp; Retail corporations operate on transactional business models optimised for high-volume inventory turnover, customer convenience, and price transparency. Clinical healthcare, however, is a relationship-based service governed by third-party reimbursement, clinical protocols, and long-term care management. Assuming that retail expertise in consumer logistics can seamlessly transition into managing acute patient care under-estimates the complexity of clinical delivery.&nbsp; &nbsp;&nbsp; Corporate strategists must recognise that medical technology is only an enabler; it cannot replace the clinical and systemic infrastructure required to treat sick patients. &nbsp;&nbsp; The Perils of Aligning Capital to Temporary Regulatory Frameworks &nbsp;&nbsp; Best Buy’s massive investment in Current Health was catalysed by temporary CMS waivers designed to expand hospital capacity during a global public health crisis. Investing hundreds of millions of dollars based on temporary emergency waivers exposes a corporation to severe policy risk.&nbsp; &nbsp;&nbsp; When Congress and CMS failed to establish a permanent reimbursement pathway for hospital-at-home care, the enterprise market stalled.&nbsp; &nbsp;&nbsp; Corporate entities should avoid committing significant capital to clinical markets until permanent, predictable reimbursement pathways are established by federal and commercial payers. Pure Technology Plays Lack Viability in Complex Clinical Settings The belief that software-as-a-service (SaaS) platforms can operate in healthcare with the same high margins and low overhead seen in other sectors is a common strategic error. Managing acute, complex care at home requires heavy human support services, including 24/7 nursing triage, device sanitisation, compliance monitoring, and patient outreach.&nbsp; &nbsp;&nbsp; These labour-intensive operations erode typical technology margins. Companies entering this space must prepare for lower-margin, services-heavy operations rather than assuming technology alone can scale clinical models. &nbsp; Brand Equity Does Not Equal Clinical Trust &nbsp;&nbsp; Retailers often assume that their strong consumer brand awareness can easily translate into clinical credibility. However, patients and healthcare providers do not view a consumer electronics retailer as a trusted source for medical treatment. &nbsp;&nbsp; Deploying retail personnel into clinical settings introduces not only operational risks, such as HIPAA data exposure, but also strategic pushback from health systems protective of their patient relationships.&nbsp; &nbsp;&nbsp; Building true "healthcare equity" requires long-term clinical collaboration, a deep understanding of patient workflows, and alignment with traditional medical providers. Without this foundation, consumer brand giants will continue to find clinical markets highly resistant to disruption.Source: <a href="https://www.healthcare.digital/single-post/clinical-ambitions-and-retail-realities-analysis-of-best-buy-s-acquisition-and-divestiture-of-curre">https://www.healthcare.digital/single-post/clinical-ambitions-and-retail-realities-analysis-of-best-buy-s-acquisition-and-divestiture-of-curre</a>

Nelson Advisors

Blog

What does the £900M NHS AI framework mean for UK healthca...

Nelson Advisors featured in Telehealth & Telecare Aware a...

Nelson Advisors referenced in leading French HealthTech p...

Nelson Advisors featured in The Institute of Chartered Ac...

Strategic Analysis of Anthropic Claude Opus 4.8: Technica...

Strategic Lessons and Takeaways from Best Buy's Acquisiti...